Veradermics (MANE) Cash from Operations (2025 - 2026)

Veradermics (MANE) reported Cash from Operations of 21168000.0 for Q1 2026, down 58.95% on a YoY basis from 51572311.75 in Q1 2025, and down 58.95% quarter-over-quarter from 13317000.0 in Q1 2025.

Veradermics (MANE) Cash from Operations (2025 - 2026) Analysis & Trends

Veradermics has reported Cash from Operations for 2 years, with the latest figure at 21168000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -1.67 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -12.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -2.49 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.43 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Veradermics 2.13 Bn 2.13 Bn - -21.17 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -21.17 Mn
Mar 31, 2026 -21.17 Mn
Mar 31, 2025 -13.32 Mn
Mar 31, 2025 -13.32 Mn